Copyright
©The Author(s) 2025.
World J Virol. Mar 25, 2025; 14(1): 100489
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.100489
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.100489
Intervention/treatment | ClinicalTrials.gov ID | Status | Phase | Sponsor |
Biological: 17D Yellow fever vaccine | NCT05332197 | Unknown status | Phase 3 | London School of Hygiene and Tropical Medicine |
Biological: STAMARIL®/biological: Yellow fever vaccine, bio-manguinhos/biological: yellow fever vaccine, institut pasteur/biological: Yellow fever vaccine, chumakov institute (fractional doses) | NCT02991495 | Completed | Phase 4 | Epicentre |
Biological: Yellow fever vaccine, institut pasteur (fractional doses) | NCT04059471 | Completed | Phase 4 | University of Oxford |
Biological: 17DD yellow fever vaccine | NCT02555072 | Completed | Phase 4 | The Immunobiological Technology Institute (Bio-Manguinhos)/Oswaldo Cruz Foundation (Fiocruz) |
Biological: SII yellow fever vaccine/biological: STAMARIL® | NCT05421611 | Recruiting | Phase 3 | Serum Institute of India Pvt. Ltd. |
Biological: 17D yellow fever vaccine/other: Deuterad water | NCT01290055 | Recruiting | Phase 4 | Sri Edupuganti |
Biological: SII yellow fever vaccine/biological: STAMARIL® | NCT05447377 | Recruiting | Phase 3 | Serum Institute of India Pvt. Ltd. |
Biological: 17DD yellow fever vaccine (fractional doses) | NCT03725618 | Unknown status | Phase 4 | Centers for Disease Control and Prevention |
Biological: YF-VAX® | NCT00694655 | Recruiting | Phase 4 | Emory University |
Placebo/biological: CYD tetravalent dengue vaccine/biological: STAMARIL® | NCT01436396 | Completed | Phase 3 | Sanofi Pasteur |
Biological: YF-VAX® | NCT05374317 | Completed | Phase 4 | United States Army Medical Research Institute of Infectious Diseases |
Biological: STAMARIL® | NCT01426243 | Completed | Phase 3 | French National Agency for Research on AIDS and Viral Hepatitis |
Biological: Yellow fever vaccine/biological: MMR vaccine | NCT03368495 | Completed | Phase 4 | Alba Maria Ropero |
Dietary supplement: vitamin A/biological: candidate plasmodium falciparum malaria vaccine/biological: MR-Vac/biological: STAMARIL® | NCT02699099 | Completed | Phase 3 | GlaxoSmithKline |
Biological: 17 DD yellow fever vaccine, biomanguinhos | NCT03132311 | Recruiting | Phase 4 | Oswaldo Cruz Foundation |
Biological: Typhoid Vi polysaccharide vaccine/biological: Yellow fever vaccine/biological: Japanese encephalitis vaccine/biological: Rabies Vaccine/biological: MenACWY-CRM vaccine | NCT01466387 | Completed | Phase 3 | Novartis |
Placebo/TAK-003 tetravalent dengue vaccine/YF-17D yellow fever vaccine | NCT03342898 | Completed | Phase 3 | Takeda |
Placebo/biological: BCG vaccine/biological: Yellow fever vaccine/drug: Vancomycin/drug: neomycin | NCT06148025 | Recruiting | Phase 4 | South Australian Health and Medical Research Institute |
- Citation: Cenci Dietrich V, Costa JMC, Oliveira MMGL, Aguiar CEO, Silva LGO, Luz MS, Lemos FFB, de Melo FF. Pathogenesis and clinical management of arboviral diseases. World J Virol 2025; 14(1): 100489
- URL: https://www.wjgnet.com/2220-3249/full/v14/i1/100489.htm
- DOI: https://dx.doi.org/10.5501/wjv.v14.i1.100489